Human Biospecimens Market Size and Forecast 2026 to 2034
The global human biospecimens market size valued at USD 14.45 billion in 2026 and projected to reach approximately USD 26.45 billion by 2034, expanding at a CAGR of 7.85% from 2026 to 2034. The market is growing due to increasing demand for personalized medicine, biomedical research, and advancements in diagnostic and drug development technologies.
Human Biospecimens Market Key Takeaways
- In terms of revenue, the global human biospecimens market was valued at USD 14.45 billion in 2026.
- It is projected to reach USD 26.45 billion by 2034.
- The market is expected to grow at a CAGR of 7.85% from 2026 to 2034.
- North America dominated the human biospecimens market with the largest market share of 40% in 2026.
- Asia Pacific is expected to grow at the fastest CAGR between 2026 and 2034.
- By specimen type, tissue specimens accounted for 30% of the market in 2026.
- By specimen type, the cfDNA/RNA & Fresh Frozen tissue segment is expected to grow at the fastest CAGR in the coming years.
- By application, the cancer research segment contributed the highest market share of 45% in 2026.
- By application, the precision medicine segment is observed to grow at the fastest CAGR during the forecast period.
- By end user, the pharma & biotech companies segment captured the major market share of 50% in 2026.
- By end user, the CROs segment is expected to grow at the fastest CAGR in the upcoming period.
- By storage type, the cold storage (-80°C or LN2) segment generated the major market share of 60% in 2026.
- By storage type, the ambient/room temp stabilized segment is emerging as the fastest growing.
- By procurement type, the retrospective (banked) samples segment accounted for 55% of the market in 2026.
- By procurement type, the prospective collection segment is observed to grow at the fastest rate during the forecast period.
Impact of AI on the Human Biospecimens Market
By improving the methods of specimen collection, processing, management, and analysis, artificial intelligence (AI) is being applied to improve human biospecimen collection, management, quality assessment, and analysis. AI algorithms increase the value of stored specimens for research and personalized medicine applications by enabling the quicker and more precise identification of biomarkers, disease patterns, and patient-specific molecular profiles. AI can optimize the management of biospecimen inventories, improving safety and reducing errors.
In biobanking, AI-driven systems enhance specimen cataloging, automate inventory management, and optimize cold storage operations, thereby reducing human error and ensuring improved sample traceability. Machine learning models can be used to identify potential sample-quality issues and flag inconsistencies, depending on the available data and system capabilities, thus maintaining the high integrity of specimens for clinical use. Overall, AI is unlocking new possibilities in biospecimen utilization by streamlining operational workflows, improving data integration, and enabling scalable, intelligent research infrastructure.
Market Overview
The human biospecimens market refers to the collection, storage, processing, and distribution of biological samples derived from the human body, such as blood, plasma, serum, tissue, urine, saliva, DNA/RNA, and other bodily fluids, for use in medical research, diagnostics, drug discovery, biomarker validation, precision medicine, and clinical trials. These biospecimens are collected, processed, stored, and distributed under applicable ethical, consent, regulatory, and quality requirements for authorized research, diagnostic development, and other permitted applications. The market is supported by increasing demand for personalized medicine, oncology research, and the rise of multi-omics studies (genomics, proteomics, transcriptomics, etc).
Human Biospecimens Market Growth Factors
- Rising Demand for Personalized Medicine: Personalized therapies require precise molecular and genetic profiling, increasing the need for high-quality human biospecimens such as blood, tissue, and DNA samples.
- Expansion in Biomedical Research: Academic institutions and pharmaceutical companies are using human samples for disease modeling, biomarker discovery, and therapeutic development.
- Advancements in Genomics and Proteomics: Breakthroughs in omics technologies enable deeper analysis of human specimens, boosting their value in diagnostics and drug discovery.
- Growth in Biobanks and Biorepositories: The expansion of biobanks worldwide is improving accessibility to diverse, well-annotated biospecimens for research and clinical trials.
- Increased R&D Spending by Pharma and Biotech: Pharmaceutical and biotechnology companies are investing heavily in R&D, creating sustained demand for ethically sourced and well-preserved human specimens.
Market Dynamics
Drivers
Growing Focus on Personalized Medicine
The demand for bio samples that facilitate molecular proteomic and genomic profiling is increasing as healthcare moves toward customized treatment regimens. DNA, blood, and tissue samples support treatment development and selection based on patient-specific biomarkers. This trend is forcing medical facilities, research institutions, and biotech companies to source high-quality specimens to develop more specialized and efficient treatments. Diverse specimen libraries are also necessary for population medicine. This factor is driving market expansion by increasing demand for innovative diagnostic and treatment approaches tailored to individual samples.
Expansion of Biobanks and Global Biorepositories
The growth of biobanks, centralized facilities that store a variety of human samples along with related clinical data, is improving access to and quality of specimens. Standardized, ethically sourced materials are available for use in academic, clinical, and commercial settings through these repositories. International networks facilitate researchers' access to uncommon and regionally specific samples, fostering cooperation and accelerating innovation. Digitized inventories can improve specimen discoverability and facilitate access across research institutions, subject to consent conditions and applicable data-transfer requirements. This driver promotes market growth.
Restraints
Ethical and Legal Concerns
There are serious regulations and considerations regarding the collection, use, and privacy of human biospecimens. Access to biospecimens may be restricted by requirements governing informed consent, donor privacy, and the permitted use of associated data. Obtaining international and institutional review board (IRB) approvals can be challenging for researchers. Any ethical violation has the potential to erode public confidence and result in legal repercussions. Moreover, high costs associated with establishing sample storage infrastructure hamper the growth of the human biospecimens market.
Limited Availability of Rare and Diverse Specimens
Biospecimens from rare disease groups and underrepresented populations are increasingly needed, but they are hard to find. This scarcity impacts the generalizability and inclusivity of study findings. It is challenging to collect and preserve a diverse range of high-quality specimens due to logistical constraints and demographic limitations. Personalized medicine initiatives may not succeed if they are not widely represented. This limitation diminishes the breadth and equity of diagnostic and therapeutic research.
Opportunity
Increasing Collaborations between Pharma and Academic Institutions
To access a variety of specimen pools, pharmaceutical companies are increasingly joining forces with hospitals, universities, and biobanks. These partnerships help improve study designs, accelerate drug discovery, and bring clinical research closer to real-world populations. Additionally, joint ventures provide academic biorepositories with infrastructure support and funding. As a result, these partnerships can improve access to rare or regionally specific specimens and global research capacity.
Segments Insights
Specimen Type Insights
What Made Tissue Specimens the Dominant Segment in the Human Biospecimens Market in 2026?
The tissue specimens segment accounted for 30% of the market in 2026. FFPE tissue represented a subsegment of tissue specimens. This is mainly due to its extensive application in histopathological analysis, with a capacity for long-term preservation and suitability for molecular testing and immunohistochemistry. FFPE tissue samples are the preferred option for biobanks and diagnostic laboratories because they are frequently utilized in cancer research, biomarker studies, and retrospective clinical trials. Their supremacy in translational research and clinical diagnostics is further supported by their capacity to preserve tissue architecture and protein integrity.
The nucleic acids segment is expected to grow at the fastest rate in the upcoming period, under which the ctDNA/cfDNA (circulating tumor DNA/cell-free DNA) sub-segment is leading the charge due to its applications in liquid biopsy genomics and precision medicine. The increasing need for high-quality molecular data further supports segmental growth. The use of ctDNA/cfDNA is increasing in clinical research because it enables non-invasive cancer diagnostics, prenatal testing, and disease progression monitoring.
Application Insights
Why did the Cancer Research Segment Dominate the Market in 2026?
The cancer research segment dominated the human biospecimens market with a 45% share in 2026, accounting for the largest share in 2026. This is mainly due to the increased burden of cancer worldwide. This significantly increased the number of cancer research studies, boosting the need for tissue, blood, and tumor samples to identify treatment responses, tumor microenvironments, and mutations. These samples are crucial for the development of immunotherapies, precision oncology, and the identification of biomarkers. The growing oncology-focused R&D and the high demand for disease-specific specimens further support segmental growth.
The precision medicine segment is expected to grow at the fastest CAGR in the coming years, driven by the growing need for customized treatments based on molecular genetics and biomarker profiling. The demand for premium human specimens, including cfDNA, FFPE tissues, and fresh frozen samples, has increased due to the growth of pharmacogenomics, rare disease diagnostics, and cancer genomics. Further speeding up the incorporation of bio-specimens in precision medicine research and clinical trials are developments in sequencing technologies and the increased focus on targeted treatments by pharmaceutical companies and healthcare providers.
End User Insights
How Does the Pharma & Biotech Companies Segment Dominate the Human Biospecimens Market?
The pharma and biotech companies segment dominated the market while capturing the largest revenue share of 50% in 2026. This is due to their extensive drug development pipelines, which heavily rely on high-quality human specimens. Using samples for preclinical research, precision drug development, and biomarker validation, these businesses frequently collaborate with biobanks and academic institutions. The ongoing demand for ethically sourced, well-annotated biospecimens is supported by investment in immunotherapies, rare disease research, and oncology. Additionally, before approval, regulatory agencies frequently demand specimen-based validation.
The contract research organizations (CROs) segment is expected to expand at the fastest rate during the projection period due to the rising outsourcing activities. Clinical research and specimen-based studies are increasingly being outsourced to CROs. They help pharmaceutical companies by locating, handling, and evaluating biospecimens. They also provide regulatory knowledge and scalability to expedite drug development schedules. Additionally, they facilitate multicenter studies and provide access to worldwide sample pools. Demand for CRO services may increase as pharmaceutical and biotechnology companies seek to optimize costs and outsource selected research activities.
Storage Type Insights
Why did the Cold Storage (-80°C or LN2) Segment Dominate the Human Biospecimens Market in 2026?
The cold storage (-80°C or LN2) segment dominated the market with share of 60% in 2026, due to its ability to sustain the effectiveness of specimens for extended periods. Cold storage maintains the structural and functional integrity of proteins, RNA, DNA, and other biomolecules. For maintaining biospecimens used in clinical trials and molecular research, it is the gold standard. Ultra-low freezers equipped with monitoring systems are used in the majority of biobanks and high-throughput laboratories to prevent sample deterioration. These storage techniques guarantee compatibility with cross-institutional research and future testing requirements. Global biobank standards and the need for long-term preservation are reinforcing the dominance of this segment.
The ambient/room temp stabilized segment is expected to grow at a rapid pace during the forecast period as it requires little infrastructure, which is inexpensive and easy to transport. Certain stabilization systems can preserve selected specimen types or analytes at ambient temperatures, depending on the formulation and storage conditions. This methodology is perfect for decentralized clinical trials, remote sampling, and environments with limited resources. It also supports green lab initiatives by reducing energy use and carbon emissions.
Procurement Type Insights
How Does the Retrospective (Banked) Samples Segment Dominate the Market in 2026?
The retrospective (banked) samples segment accounted for a reported 55% share in 2026. These samples may offer access to previously collected, annotated specimens, subject to consent conditions and applicable governance requirements, allowing researchers to conduct studies without waiting for collection cycles. Biobanks with extensive historical data provide critical insights into disease progression and treatment outcomes. These samples also reduce research timelines, support population-based studies, and enable validation of AI-based models. Their broad accessibility and existing datasets make them invaluable for hypothesis-driven research. This segment is dominating the market, driven by faster access and the availability of annotated data sets.
The prospective collection segment is expected to grow at the fastest rate over the study period due to the increased need for specialized specimens that meet specific research requirements. By defining collection criteria such as patient profiles, sample size, and timing, researchers can guarantee quality and relevance for specialized or changing study needs. This methodology facilitates sophisticated inclusion procedures and flexible trial designs. Additionally, it improves future workflows by enabling real-time data integration.
Regional Insights
What Made North America the Dominant Region in the Market in 2026?
North America dominated the human biospecimens market by holding the largest share of 40% in 2026, due to its robust biopharmaceutical industry, sophisticated healthcare infrastructure, and established biobanking networks. There are stringent regulations and ethical guidelines surrounding the collection and storage of human biospecimens for research. The rising investments in biomedical research bolstered the growth of the market within the region. U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI) initiatives support aspects of biomedical research and biospecimen resource development. To speed up innovation, academic institutions and business entities also work closely together. This region's established infrastructure with well-defined regulations and funding for cutting-edge research is driving its market dominance. The U.S. is a major player in the market. The country is home to major players in the market. Moreover, the country boasts a well-established research infrastructure, supporting market growth.
U.S. Human Biospecimens Market Size and Growth 2026 to 2034
The U.S. human biospecimens market size was exhibited at USD 4.05 billion in 2026 and is projected to be worth around USD 7.55 billion by 2034, growing at a CAGR of approximately 8.10% from 2026 to 2034.
Asia Pacific Human Biospecimens Market Trends
Asia Pacific is emerging as the fastest-growing region due to rising funding for clinical trials and the expansion of biobanks. There is a high demand for region-specific biospecimens due to the expanding population and emphasis on individualized healthcare. Asian countries are actively establishing international partnerships and updating their research infrastructure. The rising demand for personalized medicine, the high prevalence of chronic diseases, and increasing R&D activities support regional market growth.
Human Biospecimens Market Companies
- BioIVT
- Precision for Medicine
- BioChain Institute Inc.
- Conversant Bio (part of Discovery Life Sciences)
- Indivumed GmbH
- REPROCELL Inc.
- US Biolab Corporation, Inc.
- Biobank Graz (Medical University of Graz)
- ProteoGenex Inc.
- Seracare Life Sciences (part of LGC Group)
- Asterand Bioscience
- OriGene Technologies, Inc.
- Biomax Informatics AG
- Tissue Solutions Ltd.
- Human BioMolecular Research Institute (HBRI)
- AMS Bio (AMS Biotechnology)
- National Disease Research Interchange (NDRI)
- IQVIA (Biospecimen Services)
- Boca Biolistics
- BioRepository Inc.
Recent Developments
- In June 2025, Elucidate and Sapien Bioscience announced a strategic partnership to turn Sapien's extensive biobank assets into AI-ready, multimodal data products for use in drug and diagnostic development.
- In May 2025, Predictive Oncology Inc. announced that it has been leveraging its extensive biobank of over 150,000 tumor samples to advance drug discovery and biomarker research using AI and ML. This initiative follows Regeneron Pharmaceuticals' acquisition of 23andMe, which underscores the industry's shift towards utilizing real-world data for drug development.
Human Biospecimens Market Segments
By Specimen Type
- Tissue Specimens
- FFPE (Formalin-Fixed Paraffin-Embedded) Tissue
- Fresh Frozen Tissue
- Tumor Biopsies
- Normal Tissue Samples
- Biofluids
- Whole Blood
- Plasma
- Serum
- Urine
- Saliva
- CSF (Cerebrospinal Fluid)
- Fastest Growing: Plasma
- Cellular Material
- PBMCs (Peripheral Blood Mononuclear Cells)
- Buccal Cells
- Stem Cells
- Nucleic Acids
- Genomic DNA
- RNA
- ctDNA/cfDNA (circulating tumor/DNA) – Fastest Growing
By Application
- Cancer Research
- Drug Discovery and Development
- Diagnostics and Biomarker Discovery
- Translational and Genomic Research
- Precision Medicine
- Infectious Disease Studies (e.g., COVID-19, HIV, TB)
- Neurology and Cardiovascular Research
By End Use
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Hospitals and Biobanks
- Diagnostic Laboratories
- Government & Non-Profit Organizations
By Storage Type
- Cold Storage (−80°C or LN2)
- Ambient/Room Temperature Stabilized
- Cryogenic (Liquid Nitrogen, −196°C)
- Formalin-Fixed Storage
By Procurement Type
- Prospective Collection (On-Demand Collection)
- Retrospective/Banked Samples
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Table Of Content
Get a Sample
sales@precedenceresearch.com
Schedule a Meeting